OTC · Drug Manufacturers - Specialty & Generic

MGC Pharmaceuticals Limited (MGCLF) Stock

$0.27 +2.88% OTC: MGCLF Healthcare

MGC Pharmaceuticals Limited is a biopharmaceutical company dedicated to the global development and provision of plant-derived medicines. The firm manufactures and distributes both medical cannabis products and a range of non-cannabis botanical therapeutics.

Valuation

MetricValue
Price$0.27
Market Cap$12.11M
P/E Ratio-0.06
P/B Ratio-0.17
P/S Ratio5.44
EPS (TTM)$-7.07
52-Week High$5.10
52-Week Low$0.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE300.00%
ROA-208.58%
ROCE462.70%
Gross Margin37.96%
Operating Margin-457.29%
Net Margin-614.64%
Debt/Equity-1.32
Current Ratio0.19

Annual Financials (USD)

Metric20192020202120222023
Revenue$1.0M$2.0M$3.0M$5.0M$3.0M
Operating Profit$-9.0M$-12.0M$-12.0M$-15.0M$-15.0M
Net Profit$-11.0M$-19.0M$-16.0M$-20.0M$-21.0M
EPS$-9.11$-14.00$-8.30$-7.90$-7.07
Op Margin-1327.6%-567.8%-398.5%-327.5%-457.3%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$13.0M$8.0M$24.0M$19.0M$10.0M
Total Liabilities$2.0M$5.0M$10.0M$13.0M$18.0M
Cash$2.0M$2.0M$5.0M$2.0M$0
Borrowings$0$2.0M$6.0M$4.0M$10.0M

Latest News

Visa bets on stablecoins for AI micropayments Yahoo Finance Video · Jul 16, 2026 CATL Signs 5 GWh European Sodium Battery Storage Deal GuruFocus.com · Jul 16, 2026 FCC Vote on TV Cap Lifts Nexstar 8.8%, Sparks Broadcast Rally GuruFocus.com · Jul 16, 2026 Why UNH Stock Breakout Faltered After Massive Earnings Beat Investor's Business Daily · Jul 16, 2026 Goldman's Equity Underwriting Revenue Jumps 130% on SpaceX, AI Deal Boom GuruFocus.com · Jul 16, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-6.0M$-10.0M$-12.0M$-12.0M$-12.0M
Investing Cash Flow$-2.0M$-2.0M$-5.0M$-4.0M$0
Financing Cash Flow$0$10.0M$16.0M$9.0M$9.0M
Net Cash Flow$-8.0M$0$4.0M$-4.0M$-2.0M
Free Cash Flow$-7.0M$-11.0M$-15.0M$-15.0M$-12.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.37
FCF Yield-66.11%
Quick Ratio0.09
Interest Coverage-60.19
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATBPFAntibe Therapeutics Inc. $0.22 -0.19% -0.80 $11.43M 0.00%
CNPOFRIV Capital Inc. $0.08 +0.00% -0.15 $10.96M 0.00%
EIGRQEiger BioPharmaceuticals, Inc. $8.50 +6.25% -0.17 $12.59M 0.00%
FLWPFThe Flowr Corporation $0.00 — — $4265 0.00%
LVCLYLiving Cell Technologies Limited $0.03 +24.39% -11.54 $11.39M 0.00%

About MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited is a biopharmaceutical company dedicated to the global development and provision of plant-derived medicines. The firm manufactures and distributes both medical cannabis products and a range of non-cannabis botanical therapeutics. Among its key investigational drug candidates are CimetrA, which is undergoing Phase III clinical trials for the symptomatic treatment of early-stage COVID-19; CannEpil, a Phase IIb cannabis-based therapy targeting drug-resistant epilepsy; and CogniCann, currently in Phase II clinical evaluation for the symptomatic relief of dementia. Beyond its core pipeline, MGC Pharmaceuticals also offers its ArtemiC product line, various cannabinoid-focused items, and other non-pharmaceutical goods. The company further extends its services to include consulting, particularly in clinical research. Established in 2014 and headquartered in West Perth, Australia, the company previously operated as Erin Resources Limited before rebranding to MGC Pharmaceuticals Limited in December 2015.

MGC Pharmaceuticals Limited is headquartered in AU.

MGC Pharmaceuticals Limited (MGCLF) stock trades at $0.27 with a market capitalization of $12.11M. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of -0.17, price-to-sales of 5.44. Over the past 52 weeks the stock has ranged between $0.23 and $5.10, and currently trades 94.7% below its 52-week high.

On profitability, MGC Pharmaceuticals Limited generates a return on equity (ROE) of 300.00% — well above the market average, a sign of a high-quality business, return on capital employed of 462.70%, an operating margin of -457.29%, a net profit margin of -614.64%.

Official website: mgcpharma.com.au

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides